Pulmatrix (PULM) Trading Down 14.4%

Share on StockTwits

Pulmatrix Inc (NASDAQ:PULM) shares fell 14.4% during trading on Monday . The stock traded as low as $0.86 and last traded at $0.77. 14,193 shares were traded during trading, a decline of 98% from the average session volume of 699,788 shares. The stock had previously closed at $0.90.

Several brokerages have issued reports on PULM. HC Wainwright restated a “buy” rating on shares of Pulmatrix in a research note on Monday, November 19th. ValuEngine upgraded shares of Pulmatrix from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.

The firm has a market capitalization of $4.74 million, a P/E ratio of -0.08 and a beta of 1.72.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Wednesday, November 14th. The biotechnology company reported ($1.00) EPS for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.40. Equities research analysts anticipate that Pulmatrix Inc will post -6.45 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Pulmatrix (PULM) Trading Down 14.4%” was first posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://macondaily.com/2019/02/11/pulmatrix-pulm-trading-down-14-4.html.

Pulmatrix Company Profile (NASDAQ:PULM)

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).

See Also: What is the downside to momentum investing?

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply